We compared rifabutin susceptibility and rpoB mutations in 98 multi-drug-resistant strains of Mycobacterium tuberculosis (MDR-TB) by DNA sequencing and with a line probe assay using the commercially available INNO-LiPA Rif. TB kit (the LiPA). Our results indicated that rifabutin continues to remain active against MDR-TB strains harboring certain genetic alterations and also that the LiPA might be useful in identifying MDR-TB strains susceptible to rifabutin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10156-010-0057-5 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!